Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment
Korean Journal of Hematology
; : 45-48, 2011.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-720121
Responsible library:
WPRO
ABSTRACT
Thrombotic thrombocytopenic purpura (TTP) is a critical complication of treatment with mitomycin C. We retrospectively describe the case of a patient with progressive renal cell carcinoma and mitomycin-induced TTP refractory to plasma exchange and glucocorticoids; we describe the clinical course, successful management of TTP with rituximab, and follow-up of this case. Mitomycin-induced TTP resolved completely by a total of 4 infusions of rituximab 375 mg/m2 on a weekly basis, and it took up to 12 months to obtain a platelet count of >100,000/microL. Rituximab is indicated for the treatment of mitomycin-induced TTP refractory to plasma exchange and glucocorticoids, and it could improve the patient's quality of life despite the presence of underlying malignancy.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Plasma Exchange
/
Platelet Count
/
Purpura, Thrombotic Thrombocytopenic
/
Quality of Life
/
Thymine Nucleotides
/
Carcinoma, Renal Cell
/
Retrospective Studies
/
Follow-Up Studies
/
Mitomycin
/
Antibodies, Monoclonal, Murine-Derived
Type of study:
Observational study
/
Prognostic study
Aspects:
Patient-preference
Limits:
Humans
Language:
English
Journal:
Korean Journal of Hematology
Year:
2011
Document type:
Article